Description

Simple

An anticoagulant or "blood thinner" used as part of the emergency treatment of heart attacks.

Clinical

A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.

Overview

Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

Pharmacology

Indication

Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary int... Read more

Pharmacodynamic

Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. A single intravenous bolus dose from 0.15 mg/kg to 0.30 mg/kg produced rapid dose-dependent inhibition of platelet... Read more

Mechanism of action

Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block acces... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Minor bleeding US
  • Kind: experimental
    • Percent: 70-82%
  • Kind: placebo
    • Percent: 46%
  • Clinical Trial
    Immunogenicity US
  • Kind: experimental
    • Percent: 27-44%
  • Clinical Trial
    Minor bleeding US
  • Kind: experimental
    • Percent: 30%
  • Kind: placebo
    • Percent: 13%
  • Clinical Trial
    Major Bleeding US
  • Kind: experimental
    • Percent: 24%
  • Kind: placebo
    • Percent: 12%
  • Clinical Trial
    Major Bleeding US
  • Kind: experimental
    • Percent: 17-21%
  • Kind: placebo
    • Percent: 18%
  • Clinical Trial
    Back Pain US
  • Kind: experimental
    • Percent: 18%
  • Kind: placebo
    • Percent: 14%
  • Clinical Trial
    Bleeding requiring transfusion US
  • Kind: experimental
    • Percent: 15%
  • Kind: placebo
    • Percent: 9%
  • Clinical Trial
    Bleeding requiring transfusion US
  • Kind: experimental
    • Percent: 7-13%
  • Kind: placebo
    • Percent: 15%
  • Clinical Trial
    Hypotension US
  • Kind: experimental
    • Percent: 14%
  • Kind: placebo
    • Percent: 10%
  • Clinical Trial
    Hypotension US
  • Kind: experimental
    • Percent: 14%
  • Kind: placebo
    • Percent: 10%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 14%
  • Kind: placebo
    • Percent: 12%
  • Clinical Trial
    Chest Pain US
  • Kind: experimental
    • Percent: 11%
  • Kind: placebo
    • Percent: 9%
  • Clinical Trial
    Vomiting US
  • Kind: experimental
    • Percent: 7%
  • Kind: placebo
    • Percent: 7%
  • Clinical Trial
    Thrombocytopenia requiring transfusion US
  • Kind: experimental
    • Percent: 1-6%
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 6%
  • Kind: placebo
    • Percent: 5%
  • Clinical Trial
    Immunogenicity US
  • Kind: experimental
    • Percent: 6%
  • Clinical Trial
    Thrombocytopenia US
  • Kind: experimental
    • Percent: 5%
  • Clinical Trial
    Thrombocytopenia US
  • Kind: experimental
    • Percent: 3-5%
  • Clinical Trial
    Bradycardia US
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Pain US
  • Kind: experimental
    • Percent: 5%
  • Clinical Trial
    Injection site pain US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 3%
  • Clinical Trial
    Severe Thrombocytopenia US
  • Kind: experimental
    • Percent: 1-2%
  • Clinical Trial
    Profound thrombocytopenia US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Peripheral Edema US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Dyspepsia US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Anxiety US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Ventricular Tachycardia US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Pseudoaneurysm US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Incisional Pain US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Pruritus US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Abnormal vision US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Edema US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Wound US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Abscess US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Cellulitis US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Peripheral coldness US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Injection site pain US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Dry Mouth US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Pallor US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Diabetes Mellitus US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hyperkalemia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Bullous eruption US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Enlarged abdomen US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Inflammation US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Drug Toxicity US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Nodal arrhythmia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Complete AV Block US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Embolism US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial

    Contraindications

    • Regions: US
    • Patient Conditions:
        • Name: History of vasculitis
        • Drugbank Id: DBCOND0107432
    • Regions: US
    • Patient Conditions:
        • Name: Uncontrolled Hypertension
        • Drugbank Id: DBCOND0043537
    • Regions: US
    • Patient Conditions:
        • Name: Aneurysm
        • Drugbank Id: DBCOND0020220
    • Regions: US
    • Patient Conditions:
        • Name: Arterial malformation
        • Drugbank Id: DBCOND0107431
    • Regions: US
    • With Drugs:
        • Name: Dextran
        • Drugbank Id: DB09255
    • Regions: US
    • With Categories:
        • Name: Anticoagulants
        • Drugbank Id: DBCAT000007
        • Mesh Id: D000925
    • Regions: US
    • Patient Conditions:
        • Name: Bleeding diathesis
        • Drugbank Id: DBCOND0099556
    • Regions: US
    • Patient Conditions:
        • Name: History of cerebrovascular accident
        • Drugbank Id: DBCOND0107399
    • Regions: US
    • Patient Conditions:
        • Name: History of genitourinary bleeding
        • Drugbank Id: DBCOND0107428
    • Regions: US
    • Patient Conditions:
        • Name: History of gastrointestinal bleeding
        • Drugbank Id: DBCOND0107427
    • Regions: US
    • Patient Conditions:
        • Name: Intracranial Neoplasm
        • Drugbank Id: DBCOND0082428
    • Regions: US
    • Patient Conditions:
        • Name: History of trauma
        • Drugbank Id: DBCOND0107430
    • Regions: US
    • Patient Conditions:
        • Name: History of major surgery
        • Drugbank Id: DBCOND0107429
    • Regions: US
    • Patient Conditions:
        • Name: Thrombocytopenia
        • Drugbank Id: DBCOND0006608
    • Regions: US
    • Patient Conditions:
        • Name: Active internal bleeding
        • Drugbank Id: DBCOND0107389

    Food Interactions

    Avoid herbs and supplements with anticoagulant/antiplatelet activity. Additive antiplatelet activity may increase the risk of bleeding. Examples include ginseng, ginkgo, ginger, and garlic.